Author:
Sadatsafavi Mohsen,Sin Don D.,Zafari Zafar,Criner Gerard,Connett John E.,Lazarus Stephen,Han Meilan,Martinez Fernando,Albert Richard
Abstract
Abstract
Exacerbations are a hallmark of chronic obstructive pulmonary disease (COPD). Evidence suggests the presence of substantial between-individual variability (heterogeneity) in exacerbation rates. The question of whether individuals vary in their tendency towards experiencing severe (versus mild) exacerbations, or whether there is an association between exacerbation rate and severity, has not yet been studied. We used data from the MACRO Study, a 1-year randomized trial of the use of azithromycin for prevention of COPD exacerbations (United States and Canada, 2006–2010; n = 1,107, mean age = 65.2 years, 59.1% male). A parametric frailty model was combined with a logistic regression model, with bivariate random effects capturing heterogeneity in rate and severity. The average rate of exacerbation was 1.53 episodes/year, with 95% of subjects having a model-estimated rate of 0.47–4.22 episodes/year. The overall ratio of severe exacerbations to total exacerbations was 0.22, with 95% of subjects having a model-estimated ratio of 0.04–0.60. We did not confirm an association between exacerbation rate and severity (P = 0.099). A unified model, implemented in standard software, could estimate joint heterogeneity in COPD exacerbation rate and severity and can have applications in similar contexts where inference on event time and intensity is considered. We provide SAS code (SAS Institute, Inc., Cary, North Carolina) and a simulated data set to facilitate further uses of this method.
Funder
Canadian Institutes of Health Research
Canadian Respirator Research Network
Genome Canada: Genome British Columbia, Genome Quebec
Providence
St. Paul's Hospital Foundation
Prevention of Organ Failure (PROOF) Centre of Excellence
National Sanitarium Association
Tier 1 Canada Research Chair in Chronic Obstructive Pulmonary Disease
Publisher
Oxford University Press (OUP)
Reference31 articles.
1. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity;Mannino;Chest,2002
2. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013;GBD 2013 Mortality and Causes of Death Collaborators.;Lancet,2015
3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary;Vestbo;Am J Respir Crit Care Med,2013
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献